

National Cancer Advisory Board

Ad Hoc Subcommittee on Experimental Therapeutics

The purpose of this subcommittee is to provide advice and oversight of the NCI Experimental Therapeutics Program (NExT) and to assist the Division of Cancer Treatment and Diagnosis (DCTD) in the translation to the clinic of novel anticancer therapeutic interventions, either synthetic, natural product, or biologic that have been approved for development. In particular, academic institutions need a bridge between discovery and clinical testing, so that efficient translation of promising discoveries may take place even in the absence of development capacity or clinical expertise in the institution where the discovery was made and the NCI's NExT Program helps bridge this gap. This committee should also foster greater interactions with industry, academia, government, etc. to enhance the drug development process.

This subcommittee will also provide advice on policies, procedures and programs that will enhance the pre-clinical discovery and development of small molecules and biologics. Particular emphasis will be to provide oversight of the NCI Chemical Biology Consortium and NExT program. The goal is to optimize the functionality and output of these programs and to explore the potential contribution of current and future drug discovery and development practices to optimize strategies to preempt cancer at various stages.

Members:

Dr. William Sellers - Chair
Mr. William Goodwin
Dr. Waun Ki Hong
Dr. Kim Lyerly
Dr. Jennifer Pietenpol

Executive Secretary:

Dr. Joseph Tomaszewski
(301) 496-6711